Pharma BD Deal Intelligence
A cheap foundational bet: Pfizer paid Cellectis just $80 million upfront plus a 10% equity stake for allogeneic CAR-T rights across 27 targets, seeding what became Allogene Therapeutics—though a decade later the category still has no commercial CAR-T approvals.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer 'buys big into CAR-T' with $80M upfront + 10% equity stake + up to $185M per target — characterized as Pfizer's catch-up move against Novartis and Juno.
Pfizer transferred its 16-asset allogeneic CAR-T portfolio (originating from the 2014 Cellectis deal) to Allogene Therapeutics, retaining a 25% stake.
BioPharma Dive retrospective on the tangled Pfizer-Cellectis-Servier-Allogene chain, noting that the 2014 deal seeded a category that has yet to deliver…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer paid Cellectis $80M upfront plus a 10% equity stake (~$31M) and up to $185M per Pfizer-selected target in milestones across 15 Pfizer-chosen and 4 jointly-developed CAR-T targets. Strategically transformative—Pfizer's largest 2014 immuno-oncology entry and the foundation for what later became Allogene Therapeutics.
7K US cases/yr
Acute lymphoblastic leukemia (ALL) and adjacent CD19+ B-cell malignancies (DLBCL, CLL) were the lead indications for the Pfizer-Cellectis collaboration's CAR-T programs. ALL is curable in pediatrics but historically dismal in adult relapsed/refractory settings, with sub-20% 5-year survival before CAR-T. The collaboration also targeted solid tumor antigens — a far harder CAR-T problem still unresolved as of 2026.
In June 2014 the CAR-T landscape was bifurcated between autologous leaders — Novartis/Penn (CTL019, eventually Kymriah, approved 2017), Juno Therapeutics (JCAR015, later acquired by Celgene), Kite Pharma (KTE-C19, later Yescarta) — and the still-emerging allogeneic 'off-the-shelf' approach pioneered by Cellectis using TALEN gene editing. Pfizer's $2.92B deal ($80M upfront + ~$31M equity at 10% + up to $185M per Pfizer-selected target across 15 Pfizer + 4 joint targets) was the largest 2014 immuno-oncology entry by Pfizer and a strategic bet that allogeneic would beat autologous on cost, time-to-treatment, and scalability. Pfizer was a late entrant — Novartis and Juno were already in clinic — but the allogeneic angle was differentiated. The portfolio later seeded UCART19 (licensed by Servier 2015, advanced in CALM and PALL trials with 82% CR/CRi in optimally lymphodepleted patients per Lancet Haematology 2022) and, in April 2018, was contributed to a new Kite-Pharma-leadership-led NewCo, Allogene Therapeutics, where Pfizer retained 25% equity. The 2014 deal is now widely cited as the foundational transaction of the allogeneic CAR-T category, even though commercial validation remains ahead of Allogene as of 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Cellectis SA (this deal) | 2014 | $2.9B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Pfizer Inc. deals · Hematology deals